Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Represents Our Patients at CMS’ Listening Session on Imbruvica and ‘Alternative Therapies’

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

On November 6, 2023, CMS held a Medicare Drug Price Negotiation Patient-Focused Listening Session for the selected drug Imbruvica. Ten participants were selected to speak, including three from CLL Society – presenting a patient, provider, and patient organization perspective. We were pleased to have such strong representation and took the opportunity to share with CMS our community’s perspectives on:

  1. Day to day patient experiences
  2. Benefits and side effects of our treatment options
  3. Our patients’ experiences with access, adherence, and affordability

Please see an outline of what each of our speakers focused on here:

Download the letter here.